NEWARK, Calif.–(BUSINESS WIRE)–Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company
developing neuromodulators for use in treating aesthetic and underserved
therapeutic conditions, today announced the appointments of Dustin Sjuts
as Vice President of Strategy and Sales, Aesthetic and Therapeutic; Ben
Putman as Vice President of Digital; and Marc Korenberg as Senior
Director of Commercial Operations. In addition, Erica Bazerkanian has
been promoted to Vice President of Marketing, Aesthetics and
Therapeutics. All four positions are newly established and will report
to Todd Zavodnick, Chief Commercial Officer and President, Aesthetics &
Therapeutics, who leads the company’s commercial operations and launch
preparations for DaxibotulinumtoxinA for Injection (RT002) in the
treatment of glabellar (frown) lines.
In his new role at Revance, Mr. Sjuts will head all product sales
activities, championing strategies to enhance physician relations and
drive new product adoption. Most recently, he held leadership positions
at Nestle Skin Health, including Business Unit Head in China and Senior
Director of Marketing in the U.S. In China, he was responsible for the
medical aesthetics commercial organization, leading the development and
execution of the medical solutions strategy. Prior to this, Mr. Sjuts
was Senior Vice President of Franchise Operations for Alphaeon.
Previously, he served as Director of Sales in Eye Care and as Senior
Regional Manager of Aesthetics at Allergan.
Mr. Putman will lead digital marketing and strategy activities in his
new role at Revance, focused on delivering optimal customer outreach and
experiences. Prior to joining the Company, he served as Senior Vice
President, General Manager and Senior Vice President of Creative
Technology and Innovation at JUICE Pharma Advertising. Throughout his
advertising career, he has led digital marketing strategy efforts for
multiple pharmaceutical and healthcare clients and has worked on over a
dozen new product launches. Previously, Mr. Putman was Director of
Technology at FCB Health and Director of Web Development at Harrison &
In his new role, Mr. Korenberg will manage commercial operations
activities at Revance, including customer excellence and relationship
management, commercial analytics, commercial programs, and commercial
financial management. Most recently, he was Director of Commercial,
International at Allergan, after the acquisition of Zeltiq Aesthetics,
Inc., where Marc served as the Director of International Finance and
Operations. Prior to this, he was General Manager at Powersports East.
Mr. Korenberg began his career in corporate finance and investment
banking at UBS Investment Bank.
Ms. Bazerkanian’s new role includes responsibility for strategic
marketing, launch planning, product development and public relations.
Prior to her promotion, she served as Head, Strategic Marketing at
Revance, overseeing both aesthetic and therapeutic marketing and public
relations initiatives. Previously, she was Senior Director of Marketing
at Kythera Biopharmaceuticals, heading early market strategy and product
planning for a first-of-its-kind aesthetic injectable. Prior to this,
she worked on multiple product launches at Amgen in roles with
increasing responsibility across sales, business analysis and marketing
“Revance continues to attract accomplished talent in the industry, and
we are pleased to announce the addition of these seasoned leaders to our
commercial team,” said Zavodnick. “Each of these individuals possesses a
proven track record and will play an important role as we implement the
Revance Product Launch Velocity Plan for the successful
commercialization of Revance’s lead product candidate RT002 and expand
our presence in both aesthetics and therapeutic medicine.”
About Revance Therapeutics, Inc.
Revance Therapeutics is a biotechnology company developing
neuromodulators for use in treating aesthetic and underserved
therapeutic conditions, including muscle movement disorders and pain.
The company’s lead drug candidate, DaxibotulinumtoxinA for Injection
(RT002), is currently in development for the treatment of glabellar
lines, cervical dystonia and plantar fasciitis, with the potential to be
the first long-acting neuromodulator. Revance has developed a
proprietary, stabilizing excipient peptide technology designed to create
novel, differentiated therapies. The company has a comprehensive
pipeline based upon its peptide technology, including injectable and
topical formulations of daxibotulinumtoxinA. More information on Revance
may be found at www.revance.com.
“Revance Therapeutics” and the Revance logo are registered trademarks of
Revance Therapeutics, Inc.